Patients with higher PCDHGB7 methylation levels after treatment had a shorter OS (high vs. low (23.7 vs. 52.2 months, p = 0.012, Figure 6J) and PFS (high vs. low (13.2 vs. 39.0 months, p = 0.0037, Figure 6K), particularly those with an initial tumor evaluation of stable disease after treatment (high vs. low (6.0 vs. 37.2 months, p < 0.001) (Figure 6L). This evidence concerns the gene PCDHGB7 and neoplasm.